Exelixis Inc Drug Patent Portfolio
Exelixis Inc owns 1 orange book drug protected by 11 US patents Given below is the list of Exelixis Inc's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11141413 | Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate | 17 Apr, 2037 | Active |
| US9724342 | C-met modulator pharmaceutical compositions | 09 Jul, 2033 | Active |
| US11298349 | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds | 10 Feb, 2032 | Active |
| US10034873 | C-met modulator pharmaceutical compositions | 18 Jul, 2031 | Active |
| US10039757 | C-Met modulator pharmaceutical compositions | 18 Jul, 2031 | Active |
| US8877776 | (L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | 08 Oct, 2030 | Active |
| US11091439 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer | 15 Jan, 2030 | Active |
| US11091440 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)- N′-(4-fluorophenyl)cyclopropane-1,1 -dicarboxamide, and crystalline forms thereof for the treatment of cancer | 15 Jan, 2030 | Active |
| US11098015 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer | 15 Jan, 2030 | Active |
| US7579473 | c-Met modulators and methods of use | 14 Aug, 2026 | Active |
| US8497284 | C-met modulators and method of use | 24 Sep, 2024 | Expired |
Latest Legal Activities on Exelixis Inc's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Exelixis Inc.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 20 Apr, 2022 | US8877776 |
|
Recordation of Patent Grant Mailed
Critical
| 12 Apr, 2022 | US11298349 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 12 Apr, 2022 | US11298349 |
|
Email Notification
Critical
| 24 Mar, 2022 | US11298349 |
|
Issue Notification Mailed
Critical
| 23 Mar, 2022 | US11298349 |
| Dispatch to FDC | 18 Mar, 2022 | US11298349 |
|
Application Is Considered Ready for Issue
Critical
| 18 Mar, 2022 | US11298349 |
|
Mail Response to 312 Amendment (PTO-271)
Critical
| 10 Mar, 2022 | US11298349 |
|
Email Notification
Critical
| 10 Mar, 2022 | US11298349 |
|
Response to Amendment under Rule 312
Critical
| 04 Mar, 2022 | US11298349 |
|
Pubs Case Remand to TC
Critical
| 01 Mar, 2022 | US11298349 |
|
Email Notification
Critical
| 28 Feb, 2022 | US11298349 |
| Mail PUB other miscellaneous communication to applicant | 28 Feb, 2022 | US11298349 |
|
Amendment after Notice of Allowance (Rule 312)
Critical
| 28 Feb, 2022 | US11298349 |
| PUB Other miscellaneous communication to applicant | 24 Feb, 2022 | US11298349 |
Exelixis Inc Drug Patents' Oppositions Filed in EPO
Exelixis Inc drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Dec 05, 2013, by Actavis Group Ptc Ehf. This opposition was filed on patent number EP10701175A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP12704492A | Aug, 2022 | STADA Arzneimittel AG | Revoked |
| EP11740764A | Jul, 2022 | Generics (U.K.) Limited | Granted and Under Opposition |
| EP11740764A | Jul, 2022 | STADA Arzneimittel AG | Granted and Under Opposition |
| EP11740764A | Jul, 2022 | Teva Pharmaceutical Industries Ltd | Granted and Under Opposition |
| EP10701175A | Dec, 2013 | Ladendorf, Oliver | Patent maintained as amended |
| EP10701175A | Dec, 2013 | Gallafent, Alison | Patent maintained as amended |
| EP10701175A | Dec, 2013 | Actavis Group PTC ehf | Patent maintained as amended |
Exelixis Inc's Family Patents
Exelixis Inc drugs have patent protection in a total of 34 countries. It's US patent count contributes only to 28.8% of its total global patent coverage. Click
below to unlock the full patent family tree.
Exelixis Inc Drug List
Given below is the complete list of Exelixis Inc's drugs and the patents protecting them.
1. Cabometyx
Cabometyx is protected by 11 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11141413 | Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate |
17 Apr, 2037
(12 years from now)
| Active |
| US9724342 | C-met modulator pharmaceutical compositions |
09 Jul, 2033
(8 years from now)
| Active |
| US11298349 | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds |
10 Feb, 2032
(7 years from now)
| Active |
| US10034873 | C-met modulator pharmaceutical compositions |
18 Jul, 2031
(6 years from now)
| Active |
| US10039757 | C-Met modulator pharmaceutical compositions |
18 Jul, 2031
(6 years from now)
| Active |
| US8877776 | (L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
08 Oct, 2030
(5 years from now)
| Active |
| US11091439 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer |
15 Jan, 2030
(5 years from now)
| Active |
| US11091440 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)- N′-(4-fluorophenyl)cyclopropane-1,1 -dicarboxamide, and crystalline forms thereof for the treatment of cancer |
15 Jan, 2030
(5 years from now)
| Active |
| US11098015 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer |
15 Jan, 2030
(5 years from now)
| Active |
| US7579473 | c-Met modulators and methods of use |
14 Aug, 2026
(1 year, 8 months from now)
| Active |
| US8497284 | C-met modulators and method of use |
24 Sep, 2024
(2 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cabometyx's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List